OS Therapies Incorporated (NYSEAMERICAN:OSTX) Short Interest Up 82.1% in December
by Tristan Rich · The Markets DailyOS Therapies Incorporated (NYSEAMERICAN:OSTX – Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 389,268 shares, an increase of 82.1% from the November 30th total of 213,747 shares. Based on an average daily trading volume, of 533,104 shares, the short-interest ratio is currently 0.7 days. Currently, 1.2% of the shares of the company are short sold. Currently, 1.2% of the shares of the company are short sold. Based on an average daily trading volume, of 533,104 shares, the short-interest ratio is currently 0.7 days.
Hedge Funds Weigh In On OS Therapies
A number of hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new stake in shares of OS Therapies during the third quarter worth about $29,000. Mercer Global Advisors Inc. ADV purchased a new position in OS Therapies in the 3rd quarter worth approximately $40,000. Ground Swell Capital LLC bought a new position in OS Therapies in the 3rd quarter worth approximately $40,000. CM Management LLC boosted its stake in OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $784,000 after purchasing an additional 25,000 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in OS Therapies during the 2nd quarter valued at approximately $47,000.
OS Therapies Price Performance
Shares of NYSEAMERICAN OSTX opened at $1.51 on Friday. The stock has a market cap of $53.17 million, a PE ratio of -1.84 and a beta of -4.02. OS Therapies has a 1 year low of $1.12 and a 1 year high of $7.00. The firm has a fifty day moving average price of $1.77 and a 200-day moving average price of $1.89.
OS Therapies (NYSEAMERICAN:OSTX – Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter. On average, research analysts expect that OS Therapies will post -0.64 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on OSTX shares. Lake Street Capital cut their price objective on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. D. Boral Capital reiterated a “buy” rating and set a $20.00 target price on shares of OS Therapies in a research report on Monday, December 15th. Finally, Zacks Research raised OS Therapies from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.
Read Our Latest Research Report on OSTX
OS Therapies Company Profile
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.